Leiomyosarcoma of the rectum: what role does adjuvant therapy play?
Leiomyosarcoma of the rectum is an exceedingly rare malignancy and for this reason the literature fails to provide definitive management guidelines with regard to the place of adjuvant therapies. The role of radiotherapy (RT) is often downplayed on the basis of articles written at a time when state-of-the art RT equipment was unavailable. A case of leiomyosarcoma of the rectum is presented and the literature is reviewed. Because the rarity of this tumour type virtually precludes a prospective randomized trial of adjuvant therapies, the authors recommend (in otherwise fit patients) postoperative pelvic RT because its morbidity is minimal. Smaller tumours may benefit to a greater extent than those lesions that are large at presentation and thereby run a worse clinical course.
Kiffer
J D
JD
Austin and Repatriation Medical Centre, West Heidelberg, Victoria, Australia.
Castles
L
L
Quong
G G
GG
Feigen
M
M
D006801:Humans; D007890:Leiomyosarcoma / Q000532:radiotherapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000532:radiotherapy* / Q000601:surgery